U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Early Unfavorable Hodgkin Lymphoma

MedGen UID:
378869
•Concept ID:
C2348370
•
Neoplastic Process

Definition

An early Hodgkin lymphoma with unfavorable prognosis. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVEarly Unfavorable Hodgkin Lymphoma

Professional guidelines

PubMed

Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation.
Gunther JR, Fanale MA, Reddy JP, Akhtari M, Smith GL, Pinnix CC, Milgrom SA, Yehia ZA, Allen PK, Osborne EM, Mawlawi O, Dabaja BS
Int J Radiat Oncol Biol Phys 2016 Sep 1;96(1):110-8. Epub 2016 Apr 13 doi: 10.1016/j.ijrobp.2016.03.052. PMID: 27325479Free PMC Article
Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial.
Behringer K, Thielen I, Mueller H, Goergen H, Eibl AD, Rosenbrock J, Halbsguth T, Eichenauer DA, Fuchs M, Reiners KS, Renno JH, van der Ven K, Kuehr M, von Wolff M, Diehl V, Engert A, Borchmann P
Ann Oncol 2012 Jul;23(7):1818-25. Epub 2012 Jan 6 doi: 10.1093/annonc/mdr575. PMID: 22228451

Recent clinical studies

Etiology

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B
J Clin Oncol 2023 Feb 20;41(6):1193-1199. Epub 2022 Dec 12 doi: 10.1200/JCO.22.02355. PMID: 36508302
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A
Lancet Oncol 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X. PMID: 33539742
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, Sasse S, Sökler M, Kerkhoff A, Mathas S, Hüttmann A, Bormann M, Zimmermann A, Mettler J, Fuchs M, von Tresckow B, Baues C, Rosenwald A, Klapper W, Kobe C, Borchmann P, Engert A
JAMA Oncol 2020 Jun 1;6(6):872-880. doi: 10.1001/jamaoncol.2020.0750. PMID: 32352505Free PMC Article
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J
J Clin Oncol 2017 Jun 1;35(16):1786-1794. Epub 2017 Mar 14 doi: 10.1200/JCO.2016.68.6394. PMID: 28291393
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group
Lancet 2015 May 9;385(9980):1853-62. Epub 2015 Mar 19 doi: 10.1016/S0140-6736(15)60165-9. PMID: 25796459

Diagnosis

PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A
Lancet Oncol 2021 Feb;22(2):223-234. doi: 10.1016/S1470-2045(20)30601-X. PMID: 33539742
Hodgkin lymphoma in elderly patients.
Borchmann S, Engert A, Böll B
Curr Opin Oncol 2018 Sep;30(5):308-316. doi: 10.1097/CCO.0000000000000464. PMID: 29994901
Treatment of early-stage Hodgkin lymphoma.
Engert A, Raemaekers J
Semin Hematol 2016 Jul;53(3):165-70. Epub 2016 May 12 doi: 10.1053/j.seminhematol.2016.05.004. PMID: 27496307
Refractory Hodgkin lymphoma.
von Tresckow B, Engert A
Curr Opin Oncol 2013 Sep;25(5):463-9. doi: 10.1097/01.cco.0000432524.62475.60. PMID: 23942291
Hodgkin lymphoma.
Gobbi PG, Ferreri AJ, Ponzoni M, Levis A
Crit Rev Oncol Hematol 2013 Feb;85(2):216-37. Epub 2012 Aug 4 doi: 10.1016/j.critrevonc.2012.07.002. PMID: 22867814

Therapy

Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup
J Clin Oncol 2023 Jan 10;41(2):327-335. Epub 2022 Jul 22 doi: 10.1200/JCO.21.01281. PMID: 35867960
Mexican consensus on Hodgkin's lymphoma.
Álvarez-Vera JL, Aguilar-Luevano J, Alcívar-Cedeño LM, Arana-Luna LL, Arteaga-Ortiz L, Báez-Islas PE, Carolina-Reynoso A, Cesarman-Maus G, Peña-Celaya JA, Espitia-Ríos ME, Fermín-Caminero DJ, Flores-Patricio W, García-Camacho AS, Guzmán-Mora PG, Hernández-Colín AK, Hernández-Ruiz E, Herrera-Olivares W, Jacobo-Medrano E, Loera-Fragoso SJ, Macías-Flores JP, Martínez-Ramírez MA, Medina-Guzmán L, Milán-Salvatierra AI, Montoya-Jiménez L, Morales-Adrián JJ, Mujica-Martínez A, Nava-Villegas L, Orellana-Garibay JJ, Palma-Moreno OG, Pérez-Zúñiga JM, Pérez-Gómez KD, Pichardo-Cepín YM, Rojas-Castillejos F, Romero-Martínez E, Romero-Rodelo H, Segura-García A, Silva-Vera K, Tapía-Enríquez AL, Teomitzi-Sánchez Ó, Tepepa-Flores F, Vilchis-González SP, Villela-Peña A, Guerra-Alarcón LV, Reséndiz-Olea R, Banda-García L, Paredes-Lozano EP, Alvarado-Ibarra M
Gac Med Mex 2021;157(Suppl 2):S1-S16. doi: 10.24875/GMM.M21000534. PMID: 34324483
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ, Goergen H, Keller U, Meissner J, Ordemann R, Halbsguth TV, Sasse S, Sökler M, Kerkhoff A, Mathas S, Hüttmann A, Bormann M, Zimmermann A, Mettler J, Fuchs M, von Tresckow B, Baues C, Rosenwald A, Klapper W, Kobe C, Borchmann P, Engert A
JAMA Oncol 2020 Jun 1;6(6):872-880. doi: 10.1001/jamaoncol.2020.0750. PMID: 32352505Free PMC Article
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J
J Clin Oncol 2017 Jun 1;35(16):1786-1794. Epub 2017 Mar 14 doi: 10.1200/JCO.2016.68.6394. PMID: 28291393
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J; AETHERA Study Group
Lancet 2015 May 9;385(9980):1853-62. Epub 2015 Mar 19 doi: 10.1016/S0140-6736(15)60165-9. PMID: 25796459

Prognosis

Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup
J Clin Oncol 2023 Jan 10;41(2):327-335. Epub 2022 Jul 22 doi: 10.1200/JCO.21.01281. PMID: 35867960
Mexican consensus on Hodgkin's lymphoma.
Álvarez-Vera JL, Aguilar-Luevano J, Alcívar-Cedeño LM, Arana-Luna LL, Arteaga-Ortiz L, Báez-Islas PE, Carolina-Reynoso A, Cesarman-Maus G, Peña-Celaya JA, Espitia-Ríos ME, Fermín-Caminero DJ, Flores-Patricio W, García-Camacho AS, Guzmán-Mora PG, Hernández-Colín AK, Hernández-Ruiz E, Herrera-Olivares W, Jacobo-Medrano E, Loera-Fragoso SJ, Macías-Flores JP, Martínez-Ramírez MA, Medina-Guzmán L, Milán-Salvatierra AI, Montoya-Jiménez L, Morales-Adrián JJ, Mujica-Martínez A, Nava-Villegas L, Orellana-Garibay JJ, Palma-Moreno OG, Pérez-Zúñiga JM, Pérez-Gómez KD, Pichardo-Cepín YM, Rojas-Castillejos F, Romero-Martínez E, Romero-Rodelo H, Segura-García A, Silva-Vera K, Tapía-Enríquez AL, Teomitzi-Sánchez Ó, Tepepa-Flores F, Vilchis-González SP, Villela-Peña A, Guerra-Alarcón LV, Reséndiz-Olea R, Banda-García L, Paredes-Lozano EP, Alvarado-Ibarra M
Gac Med Mex 2021;157(Suppl 2):S1-S16. doi: 10.24875/GMM.M21000534. PMID: 34324483
Balancing risk and benefit in early-stage classical Hodgkin lymphoma.
Bröckelmann PJ, Sasse S, Engert A
Blood 2018 Apr 12;131(15):1666-1678. Epub 2018 Mar 2 doi: 10.1182/blood-2017-10-772665. PMID: 29500174
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J
J Clin Oncol 2017 Jun 1;35(16):1786-1794. Epub 2017 Mar 14 doi: 10.1200/JCO.2016.68.6394. PMID: 28291393
Hodgkin lymphoma.
Gobbi PG, Ferreri AJ, Ponzoni M, Levis A
Crit Rev Oncol Hematol 2013 Feb;85(2):216-37. Epub 2012 Aug 4 doi: 10.1016/j.critrevonc.2012.07.002. PMID: 22867814

Clinical prediction guides

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial.
Bröckelmann PJ, Bühnen I, Meissner J, Trautmann-Grill K, Herhaus P, Halbsguth TV, Schaub V, Kerkhoff A, Mathas S, Bormann M, Dickhut A, Kaul H, Fuchs M, Kobe C, Baues C, Borchmann P, Engert A, von Tresckow B
J Clin Oncol 2023 Feb 20;41(6):1193-1199. Epub 2022 Dec 12 doi: 10.1200/JCO.22.02355. PMID: 36508302
Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma.
Abramson JS, Bengston E, Redd R, Barnes JA, Takvorian T, Sokol L, Lansigan F, Armand P, Shah B, Jacobsen E, Martignetti R, Turba E, Metzler S, Patterson V, LaCasce AS, Bello CM
Blood Adv 2023 Apr 11;7(7):1130-1136. doi: 10.1182/bloodadvances.2022008420. PMID: 36053786Free PMC Article
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup
J Clin Oncol 2023 Jan 10;41(2):327-335. Epub 2022 Jul 22 doi: 10.1200/JCO.21.01281. PMID: 35867960
Quality indicators for early stage Hodgkin's lymphoma.
Roos DE, Tee HC
J Med Imaging Radiat Oncol 2017 Aug;61(4):550-556. Epub 2017 Mar 27 doi: 10.1111/1754-9485.12602. PMID: 28345307
Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.
Iberri DJ, Hoppe RT, Advani RH
Curr Treat Options Oncol 2015 Sep;16(9):45. doi: 10.1007/s11864-015-0360-6. PMID: 26187795

Recent systematic reviews

Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.
Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B
Cochrane Database Syst Rev 2017 May 25;5(5):CD007941. doi: 10.1002/14651858.CD007941.pub3. PMID: 28541603Free PMC Article
Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
Sickinger MT, von Tresckow B, Kobe C, Engert A, Borchmann P, Skoetz N
Cochrane Database Syst Rev 2015 Jan 9;1(1):CD010533. doi: 10.1002/14651858.CD010533.pub2. PMID: 25572491Free PMC Article
Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
Bauer K, Skoetz N, Monsef I, Engert A, Brillant C
Cochrane Database Syst Rev 2011 Aug 10;(8):CD007941. doi: 10.1002/14651858.CD007941.pub2. PMID: 21833963

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...